CS195254B2 - Method of producing tri-p-toluensulphonate s-adenosyl-l-methionine - Google Patents

Method of producing tri-p-toluensulphonate s-adenosyl-l-methionine Download PDF

Info

Publication number: CS195254B2
Authority: CS; Czechoslovakia
Prior art keywords: sam; methionine; adenosyl; salt; tri
Prior art date: 1972-08-02

Application number

CS735374A

Other languages

Czech (cs)

English (en)

Inventor

Alberto Fiecchi

Original Assignee

Bio Research S A S

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1972-08-02

Filing date

1973-07-26

Publication date

1980-01-31

1973-07-26 Application filed by Bio Research S A S filed Critical Bio Research S A S

1980-01-31 Publication of CS195254B2 publication Critical patent/CS195254B2/cs

Links

MEFKEPWMEQBLKI-AIRLBKTGSA-N S-adenosyl-L-methioninate Chemical compound O[C@@H]1[C@H](O)[C@@H](C[S+](CC[C@H](N)C([O-])=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 MEFKEPWMEQBLKI-AIRLBKTGSA-N 0.000 title claims abstract description 13
238000000034 method Methods 0.000 title claims description 33
JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 claims abstract description 45
150000003839 salts Chemical class 0.000 claims abstract description 29
239000007864 aqueous solution Substances 0.000 claims abstract description 14
239000000243 solution Substances 0.000 claims description 33
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 30
230000008569 process Effects 0.000 claims description 23
ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 claims description 15
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 15
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 12
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 12
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 9
BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 claims description 7
235000019441 ethanol Nutrition 0.000 claims description 6
229960004452 methionine Drugs 0.000 claims description 5
239000003960 organic solvent Substances 0.000 claims description 4
239000002244 precipitate Substances 0.000 claims description 4
238000002360 preparation method Methods 0.000 claims description 4
210000005253 yeast cell Anatomy 0.000 claims description 3
KXKVLQRXCPHEJC-UHFFFAOYSA-N acetic acid trimethyl ester Natural products COC(C)=O KXKVLQRXCPHEJC-UHFFFAOYSA-N 0.000 claims description 2
239000007858 starting material Substances 0.000 claims description 2
XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 claims 1
230000004060 metabolic process Effects 0.000 abstract description 18
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract description 17
239000002253 acid Substances 0.000 abstract description 7
150000002632 lipids Chemical class 0.000 abstract description 5
150000001412 amines Chemical class 0.000 abstract description 4
150000003943 catecholamines Chemical class 0.000 abstract description 2
239000008194 pharmaceutical composition Substances 0.000 abstract 1
239000000546 pharmaceutical excipient Substances 0.000 abstract 1
230000001376 precipitating effect Effects 0.000 abstract 1
150000001875 compounds Chemical class 0.000 description 31
239000000047 product Substances 0.000 description 18
239000000126 substance Substances 0.000 description 16
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 15
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 13
208000035475 disorder Diseases 0.000 description 11
238000002474 experimental method Methods 0.000 description 11
239000011347 resin Substances 0.000 description 11
229920005989 resin Polymers 0.000 description 11
238000011282 treatment Methods 0.000 description 11
210000004369 blood Anatomy 0.000 description 10
239000008280 blood Substances 0.000 description 10
HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 10
210000004027 cell Anatomy 0.000 description 9
VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 8
241000700159 Rattus Species 0.000 description 8
-1 anion chloride sulfate tri-p-toluenesulfonate Chemical class 0.000 description 8
230000000694 effects Effects 0.000 description 8
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 7
230000037396 body weight Effects 0.000 description 7
230000000144 pharmacologic effect Effects 0.000 description 7
230000001225 therapeutic effect Effects 0.000 description 7
QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 6
QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 6
239000003814 drug Substances 0.000 description 6
238000001914 filtration Methods 0.000 description 6
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 6
239000000203 mixture Substances 0.000 description 6
108090000790 Enzymes Proteins 0.000 description 5
102000004190 Enzymes Human genes 0.000 description 5
WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 description 5
WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 description 5
210000004556 brain Anatomy 0.000 description 5
238000010828 elution Methods 0.000 description 5
229960004502 levodopa Drugs 0.000 description 5
238000004519 manufacturing process Methods 0.000 description 5
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 5
235000018102 proteins Nutrition 0.000 description 5
102000004169 proteins and genes Human genes 0.000 description 5
108090000623 proteins and genes Proteins 0.000 description 5
208000024891 symptom Diseases 0.000 description 5
102000004506 Blood Proteins Human genes 0.000 description 4
108010017384 Blood Proteins Proteins 0.000 description 4
240000004808 Saccharomyces cerevisiae Species 0.000 description 4
235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 4
CVSVTCORWBXHQV-UHFFFAOYSA-N creatine Chemical compound NC(=[NH2+])N(C)CC([O-])=O CVSVTCORWBXHQV-UHFFFAOYSA-N 0.000 description 4
230000002255 enzymatic effect Effects 0.000 description 4
230000006872 improvement Effects 0.000 description 4
238000001990 intravenous administration Methods 0.000 description 4
210000004185 liver Anatomy 0.000 description 4
230000004048 modification Effects 0.000 description 4
238000012986 modification Methods 0.000 description 4
210000000056 organ Anatomy 0.000 description 4
238000012360 testing method Methods 0.000 description 4
210000001519 tissue Anatomy 0.000 description 4
239000012608 weak cation exchange resin Substances 0.000 description 4
DPEYHNFHDIXMNV-UHFFFAOYSA-N (9-amino-3-bicyclo[3.3.1]nonanyl)-(4-benzyl-5-methyl-1,4-diazepan-1-yl)methanone dihydrochloride Chemical compound Cl.Cl.CC1CCN(CCN1Cc1ccccc1)C(=O)C1CC2CCCC(C1)C2N DPEYHNFHDIXMNV-UHFFFAOYSA-N 0.000 description 3
UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
102000004877 Insulin Human genes 0.000 description 3
108090001061 Insulin Proteins 0.000 description 3
FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 3
OKIZCWYLBDKLSU-UHFFFAOYSA-M N,N,N-Trimethylmethanaminium chloride Chemical compound [Cl-].C[N+](C)(C)C OKIZCWYLBDKLSU-UHFFFAOYSA-M 0.000 description 3
241000283973 Oryctolagus cuniculus Species 0.000 description 3
ZJUKTBDSGOFHSH-WFMPWKQPSA-N S-Adenosylhomocysteine Chemical compound O[C@@H]1[C@H](O)[C@@H](CSCC[C@H](N)C(O)=O)O[C@H]1N1C2=NC=NC(N)=C2N=C1 ZJUKTBDSGOFHSH-WFMPWKQPSA-N 0.000 description 3
208000034189 Sclerosis Diseases 0.000 description 3
238000010521 absorption reaction Methods 0.000 description 3
150000007513 acids Chemical class 0.000 description 3
230000009471 action Effects 0.000 description 3
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
238000005842 biochemical reaction Methods 0.000 description 3
230000000035 biogenic effect Effects 0.000 description 3
230000015572 biosynthetic process Effects 0.000 description 3
238000006243 chemical reaction Methods 0.000 description 3
235000005911 diet Nutrition 0.000 description 3
239000003925 fat Substances 0.000 description 3
229940125396 insulin Drugs 0.000 description 3
229930182817 methionine Natural products 0.000 description 3
229910052760 oxygen Inorganic materials 0.000 description 3
239000001301 oxygen Substances 0.000 description 3
WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 3
229920001467 poly(styrenesulfonates) Polymers 0.000 description 3
230000022558 protein metabolic process Effects 0.000 description 3
230000009467 reduction Effects 0.000 description 3
230000002829 reductive effect Effects 0.000 description 3
230000033764 rhythmic process Effects 0.000 description 3
208000010110 spontaneous platelet aggregation Diseases 0.000 description 3
229910021653 sulphate ion Inorganic materials 0.000 description 3
UCTWMZQNUQWSLP-SECBINFHSA-N (S)-adrenaline Chemical compound CNC[C@@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-SECBINFHSA-N 0.000 description 2
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
102000009027 Albumins Human genes 0.000 description 2
108010088751 Albumins Proteins 0.000 description 2
206010003210 Arteriosclerosis Diseases 0.000 description 2
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
241000235646 Cyberlindnera jadinii Species 0.000 description 2
QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical compound [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 description 2
208000004930 Fatty Liver Diseases 0.000 description 2
102000015779 HDL Lipoproteins Human genes 0.000 description 2
108010010234 HDL Lipoproteins Proteins 0.000 description 2
206010019708 Hepatic steatosis Diseases 0.000 description 2
NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
241000282412 Homo Species 0.000 description 2
241001465754 Metazoa Species 0.000 description 2
LSDPWZHWYPCBBB-UHFFFAOYSA-N Methanethiol Chemical compound SC LSDPWZHWYPCBBB-UHFFFAOYSA-N 0.000 description 2
102000016397 Methyltransferase Human genes 0.000 description 2
108060004795 Methyltransferase Proteins 0.000 description 2
241000699666 Mus <mouse, genus> Species 0.000 description 2
DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 2
208000030713 Parkinson disease and parkinsonism Diseases 0.000 description 2
208000007536 Thrombosis Diseases 0.000 description 2
229930003779 Vitamin B12 Natural products 0.000 description 2
238000009825 accumulation Methods 0.000 description 2
239000004480 active ingredient Substances 0.000 description 2
230000001154 acute effect Effects 0.000 description 2
UCTWMZQNUQWSLP-UHFFFAOYSA-N adrenaline Chemical compound CNCC(O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-UHFFFAOYSA-N 0.000 description 2
230000001195 anabolic effect Effects 0.000 description 2
150000001450 anions Chemical group 0.000 description 2
230000002785 anti-thrombosis Effects 0.000 description 2
208000011775 arteriosclerosis disease Diseases 0.000 description 2
AYJRCSIUFZENHW-UHFFFAOYSA-L barium carbonate Chemical compound [Ba+2].[O-]C([O-])=O AYJRCSIUFZENHW-UHFFFAOYSA-L 0.000 description 2
TZCXTZWJZNENPQ-UHFFFAOYSA-L barium sulfate Chemical compound [Ba+2].[O-]S([O-])(=O)=O TZCXTZWJZNENPQ-UHFFFAOYSA-L 0.000 description 2
230000009286 beneficial effect Effects 0.000 description 2
230000008901 benefit Effects 0.000 description 2
230000023852 carbohydrate metabolic process Effects 0.000 description 2
235000021256 carbohydrate metabolism Nutrition 0.000 description 2
230000002490 cerebral effect Effects 0.000 description 2
230000008859 change Effects 0.000 description 2
235000012000 cholesterol Nutrition 0.000 description 2
AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 description 2
229960003624 creatine Drugs 0.000 description 2
239000006046 creatine Substances 0.000 description 2
OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 2
230000006378 damage Effects 0.000 description 2
206010012601 diabetes mellitus Diseases 0.000 description 2
230000037213 diet Effects 0.000 description 2
201000010099 disease Diseases 0.000 description 2
VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 2
238000001035 drying Methods 0.000 description 2
208000010706 fatty liver disease Diseases 0.000 description 2
239000012530 fluid Substances 0.000 description 2
BPMFZUMJYQTVII-UHFFFAOYSA-N guanidinoacetic acid Chemical compound NC(=N)NCC(O)=O BPMFZUMJYQTVII-UHFFFAOYSA-N 0.000 description 2
UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 2
KUBCEEMXQZUPDQ-UHFFFAOYSA-N hordenine Chemical compound CN(C)CCC1=CC=C(O)C=C1 KUBCEEMXQZUPDQ-UHFFFAOYSA-N 0.000 description 2
239000012535 impurity Substances 0.000 description 2
238000001802 infusion Methods 0.000 description 2
238000010255 intramuscular injection Methods 0.000 description 2
238000010253 intravenous injection Methods 0.000 description 2
210000005229 liver cell Anatomy 0.000 description 2
208000019423 liver disease Diseases 0.000 description 2
230000003340 mental effect Effects 0.000 description 2
BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
230000001575 pathological effect Effects 0.000 description 2
VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 2
239000000825 pharmaceutical preparation Substances 0.000 description 2
238000001556 precipitation Methods 0.000 description 2
238000011084 recovery Methods 0.000 description 2
238000011160 research Methods 0.000 description 2
PETSAYFQSGAEQY-UHFFFAOYSA-N ricinine Chemical compound COC=1C=CN(C)C(=O)C=1C#N PETSAYFQSGAEQY-UHFFFAOYSA-N 0.000 description 2
239000000523 sample Substances 0.000 description 2
QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 2
239000002904 solvent Substances 0.000 description 2
231100000240 steatosis hepatitis Toxicity 0.000 description 2
229910052717 sulfur Inorganic materials 0.000 description 2
238000003786 synthesis reaction Methods 0.000 description 2
RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 2
230000000699 topical effect Effects 0.000 description 2
238000012546 transfer Methods 0.000 description 2
230000004614 tumor growth Effects 0.000 description 2
235000019163 vitamin B12 Nutrition 0.000 description 2
239000011715 vitamin B12 Substances 0.000 description 2
230000008673 vomiting Effects 0.000 description 2
238000005406 washing Methods 0.000 description 2
SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 description 1
OILXMJHPFNGGTO-UHFFFAOYSA-N (22E)-(24xi)-24-methylcholesta-5,22-dien-3beta-ol Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)C=CC(C)C(C)C)C1(C)CC2 OILXMJHPFNGGTO-UHFFFAOYSA-N 0.000 description 1
RQOCXCFLRBRBCS-UHFFFAOYSA-N (22E)-cholesta-5,7,22-trien-3beta-ol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)C=CCC(C)C)CCC33)C)C3=CC=C21 RQOCXCFLRBRBCS-UHFFFAOYSA-N 0.000 description 1
PHIQHXFUZVPYII-ZCFIWIBFSA-N (R)-carnitine Chemical compound C[N+](C)(C)C[C@H](O)CC([O-])=O PHIQHXFUZVPYII-ZCFIWIBFSA-N 0.000 description 1
NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 1
LBLYYCQCTBFVLH-UHFFFAOYSA-M 2-methylbenzenesulfonate Chemical compound CC1=CC=CC=C1S([O-])(=O)=O LBLYYCQCTBFVLH-UHFFFAOYSA-M 0.000 description 1
OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
OQMZNAMGEHIHNN-UHFFFAOYSA-N 7-Dehydrostigmasterol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)C=CC(CC)C(C)C)CCC33)C)C3=CC=C21 OQMZNAMGEHIHNN-UHFFFAOYSA-N 0.000 description 1
229930024421 Adenine Natural products 0.000 description 1
GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
206010001605 Alcohol poisoning Diseases 0.000 description 1
241000894006 Bacteria Species 0.000 description 1
QRYRORQUOLYVBU-VBKZILBWSA-N Carnosic acid Natural products CC([C@@H]1CC2)(C)CCC[C@]1(C(O)=O)C1=C2C=C(C(C)C)C(O)=C1O QRYRORQUOLYVBU-VBKZILBWSA-N 0.000 description 1
108010087806 Carnosine Proteins 0.000 description 1
241000700198 Cavia Species 0.000 description 1
ACTIUHUUMQJHFO-UHFFFAOYSA-N Coenzym Q10 Natural products COC1=C(OC)C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UHFFFAOYSA-N 0.000 description 1
208000020401 Depressive disease Diseases 0.000 description 1
RWSOTUBLDIXVET-UHFFFAOYSA-N Dihydrogen sulfide Chemical compound S RWSOTUBLDIXVET-UHFFFAOYSA-N 0.000 description 1
241000196324 Embryophyta Species 0.000 description 1
DNVPQKQSNYMLRS-NXVQYWJNSA-N Ergosterol Natural products CC(C)[C@@H](C)C=C[C@H](C)[C@H]1CC[C@H]2C3=CC=C4C[C@@H](O)CC[C@]4(C)[C@@H]3CC[C@]12C DNVPQKQSNYMLRS-NXVQYWJNSA-N 0.000 description 1
206010015856 Extrasystoles Diseases 0.000 description 1
241000282326 Felis catus Species 0.000 description 1
229930091371 Fructose Natural products 0.000 description 1
RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
239000005715 Fructose Substances 0.000 description 1
241000287828 Gallus gallus Species 0.000 description 1
229920002527 Glycogen Polymers 0.000 description 1
206010019233 Headaches Diseases 0.000 description 1
108010033040 Histones Proteins 0.000 description 1
208000001953 Hypotension Diseases 0.000 description 1
102000007330 LDL Lipoproteins Human genes 0.000 description 1
108010007622 LDL Lipoproteins Proteins 0.000 description 1
102000003960 Ligases Human genes 0.000 description 1
108090000364 Ligases Proteins 0.000 description 1
208000017170 Lipid metabolism disease Diseases 0.000 description 1
241000124008 Mammalia Species 0.000 description 1
206010027940 Mood altered Diseases 0.000 description 1
208000016285 Movement disease Diseases 0.000 description 1
241000699670 Mus sp. Species 0.000 description 1
206010052904 Musculoskeletal stiffness Diseases 0.000 description 1
102000003505 Myosin Human genes 0.000 description 1
108060008487 Myosin Proteins 0.000 description 1
MVAWJSIDNICKHF-UHFFFAOYSA-N N-acetylserotonin Chemical compound C1=C(O)C=C2C(CCNC(=O)C)=CNC2=C1 MVAWJSIDNICKHF-UHFFFAOYSA-N 0.000 description 1
CQOVPNPJLQNMDC-UHFFFAOYSA-N N-beta-alanyl-L-histidine Natural products NCCC(=O)NC(C(O)=O)CC1=CN=CN1 CQOVPNPJLQNMDC-UHFFFAOYSA-N 0.000 description 1
240000007711 Peperomia pellucida Species 0.000 description 1
208000000418 Premature Cardiac Complexes Diseases 0.000 description 1
206010037660 Pyrexia Diseases 0.000 description 1
208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
108010051753 Spermidine Synthase Proteins 0.000 description 1
NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
206010044565 Tremor Diseases 0.000 description 1
206010047700 Vomiting Diseases 0.000 description 1
230000003187 abdominal effect Effects 0.000 description 1
230000002378 acidificating effect Effects 0.000 description 1
239000013543 active substance Substances 0.000 description 1
230000007059 acute toxicity Effects 0.000 description 1
231100000403 acute toxicity Toxicity 0.000 description 1
229960000643 adenine Drugs 0.000 description 1
210000004100 adrenal gland Anatomy 0.000 description 1
230000002411 adverse Effects 0.000 description 1
239000000443 aerosol Substances 0.000 description 1
150000001298 alcohols Chemical class 0.000 description 1
150000001413 amino acids Chemical class 0.000 description 1
238000010171 animal model Methods 0.000 description 1
239000003957 anion exchange resin Substances 0.000 description 1
239000003146 anticoagulant agent Substances 0.000 description 1
210000000702 aorta abdominal Anatomy 0.000 description 1
210000002376 aorta thoracic Anatomy 0.000 description 1
230000036528 appetite Effects 0.000 description 1
235000019789 appetite Nutrition 0.000 description 1
230000004872 arterial blood pressure Effects 0.000 description 1
244000052616 bacterial pathogen Species 0.000 description 1
229940125717 barbiturate Drugs 0.000 description 1
RQPZNWPYLFFXCP-UHFFFAOYSA-L barium dihydroxide Chemical compound [OH-].[OH-].[Ba+2] RQPZNWPYLFFXCP-UHFFFAOYSA-L 0.000 description 1
229910001863 barium hydroxide Inorganic materials 0.000 description 1
230000001707 blastogenic effect Effects 0.000 description 1
230000008499 blood brain barrier function Effects 0.000 description 1
230000036772 blood pressure Effects 0.000 description 1
210000001218 blood-brain barrier Anatomy 0.000 description 1
210000005013 brain tissue Anatomy 0.000 description 1
150000001720 carbohydrates Chemical class 0.000 description 1
235000014633 carbohydrates Nutrition 0.000 description 1
229960004203 carnitine Drugs 0.000 description 1
229940044199 carnosine Drugs 0.000 description 1
CQOVPNPJLQNMDC-ZETCQYMHSA-N carnosine Chemical compound [NH3+]CCC(=O)N[C@H](C([O-])=O)CC1=CNC=N1 CQOVPNPJLQNMDC-ZETCQYMHSA-N 0.000 description 1
150000001767 cationic compounds Chemical class 0.000 description 1
229920001429 chelating resin Polymers 0.000 description 1
235000013330 chicken meat Nutrition 0.000 description 1
150000001805 chlorine compounds Chemical class 0.000 description 1
229960001231 choline Drugs 0.000 description 1
OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
230000001684 chronic effect Effects 0.000 description 1
231100000160 chronic toxicity Toxicity 0.000 description 1
230000007665 chronic toxicity Effects 0.000 description 1
231100000132 chronic toxicity testing Toxicity 0.000 description 1
239000012568 clinical material Substances 0.000 description 1
238000011260 co-administration Methods 0.000 description 1
235000017471 coenzyme Q10 Nutrition 0.000 description 1
ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 description 1
239000012141 concentrate Substances 0.000 description 1
239000012059 conventional drug carrier Substances 0.000 description 1
238000011443 conventional therapy Methods 0.000 description 1
230000007797 corrosion Effects 0.000 description 1
238000005260 corrosion Methods 0.000 description 1
210000000805 cytoplasm Anatomy 0.000 description 1
229940104302 cytosine Drugs 0.000 description 1
238000006114 decarboxylation reaction Methods 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
230000007812 deficiency Effects 0.000 description 1
238000004925 denaturation Methods 0.000 description 1
230000036425 denaturation Effects 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
230000006866 deterioration Effects 0.000 description 1
238000003745 diagnosis Methods 0.000 description 1
230000000378 dietary effect Effects 0.000 description 1
210000002249 digestive system Anatomy 0.000 description 1
WQABCVAJNWAXTE-UHFFFAOYSA-N dimercaprol Chemical compound OCC(S)CS WQABCVAJNWAXTE-UHFFFAOYSA-N 0.000 description 1
YWEUIGNSBFLMFL-UHFFFAOYSA-N diphosphonate Chemical compound O=P(=O)OP(=O)=O YWEUIGNSBFLMFL-UHFFFAOYSA-N 0.000 description 1
229960003638 dopamine Drugs 0.000 description 1
230000001278 effect on cholesterol Effects 0.000 description 1
230000000678 effect on lipid Effects 0.000 description 1
238000001962 electrophoresis Methods 0.000 description 1
238000006911 enzymatic reaction Methods 0.000 description 1
NGKZFDYBISXGGS-UHFFFAOYSA-N epinine Chemical compound CNCCC1=CC=C(O)C(O)=C1 NGKZFDYBISXGGS-UHFFFAOYSA-N 0.000 description 1
DNVPQKQSNYMLRS-SOWFXMKYSA-N ergosterol Chemical compound C1[C@@H](O)CC[C@]2(C)[C@H](CC[C@]3([C@H]([C@H](C)/C=C/[C@@H](C)C(C)C)CC[C@H]33)C)C3=CC=C21 DNVPQKQSNYMLRS-SOWFXMKYSA-N 0.000 description 1
229940011871 estrogen Drugs 0.000 description 1
239000000262 estrogen Substances 0.000 description 1
238000001704 evaporation Methods 0.000 description 1
230000008020 evaporation Effects 0.000 description 1
239000000706 filtrate Substances 0.000 description 1
235000019253 formic acid Nutrition 0.000 description 1
230000006870 function Effects 0.000 description 1
229940096919 glycogen Drugs 0.000 description 1
230000003394 haemopoietic effect Effects 0.000 description 1
231100000869 headache Toxicity 0.000 description 1
231100000334 hepatotoxic Toxicity 0.000 description 1
DMEGYFMYUHOHGS-UHFFFAOYSA-N heptamethylene Natural products C1CCCCCC1 DMEGYFMYUHOHGS-UHFFFAOYSA-N 0.000 description 1
229960001340 histamine Drugs 0.000 description 1
229940071490 hordenine Drugs 0.000 description 1
229940088597 hormone Drugs 0.000 description 1
239000005556 hormone Substances 0.000 description 1
229910052739 hydrogen Inorganic materials 0.000 description 1
XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
150000004679 hydroxides Chemical class 0.000 description 1
229910001411 inorganic cation Inorganic materials 0.000 description 1
206010022437 insomnia Diseases 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
239000007927 intramuscular injection Substances 0.000 description 1
238000005342 ion exchange Methods 0.000 description 1
239000003456 ion exchange resin Substances 0.000 description 1
229920003303 ion-exchange polymer Polymers 0.000 description 1
150000002500 ions Chemical class 0.000 description 1
230000007794 irritation Effects 0.000 description 1
210000003734 kidney Anatomy 0.000 description 1
210000003292 kidney cell Anatomy 0.000 description 1
230000002045 lasting effect Effects 0.000 description 1
230000003902 lesion Effects 0.000 description 1
230000037356 lipid metabolism Effects 0.000 description 1
239000007788 liquid Substances 0.000 description 1
208000012866 low blood pressure Diseases 0.000 description 1
210000004072 lung Anatomy 0.000 description 1
210000004698 lymphocyte Anatomy 0.000 description 1
230000036244 malformation Effects 0.000 description 1
239000000463 material Substances 0.000 description 1
238000005259 measurement Methods 0.000 description 1
230000011987 methylation Effects 0.000 description 1
238000007069 methylation reaction Methods 0.000 description 1
230000007510 mood change Effects 0.000 description 1
210000003205 muscle Anatomy 0.000 description 1
239000005445 natural material Substances 0.000 description 1
230000000926 neurological effect Effects 0.000 description 1
229960003966 nicotinamide Drugs 0.000 description 1
235000005152 nicotinamide Nutrition 0.000 description 1
239000011570 nicotinamide Substances 0.000 description 1
SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 description 1
229960002715 nicotine Drugs 0.000 description 1
229910052757 nitrogen Inorganic materials 0.000 description 1
229960002748 norepinephrine Drugs 0.000 description 1
238000010606 normalization Methods 0.000 description 1
235000015097 nutrients Nutrition 0.000 description 1
230000009965 odorless effect Effects 0.000 description 1
238000007911 parenteral administration Methods 0.000 description 1
230000036961 partial effect Effects 0.000 description 1
231100000915 pathological change Toxicity 0.000 description 1
230000036285 pathological change Effects 0.000 description 1
235000010987 pectin Nutrition 0.000 description 1
239000001814 pectin Substances 0.000 description 1
229920001277 pectin Polymers 0.000 description 1
229960000292 pectin Drugs 0.000 description 1
RGSFGYAAUTVSQA-UHFFFAOYSA-N pentamethylene Natural products C1CCCC1 RGSFGYAAUTVSQA-UHFFFAOYSA-N 0.000 description 1
230000002688 persistence Effects 0.000 description 1
150000003904 phospholipids Chemical class 0.000 description 1
DLYUQMMRRRQYAE-UHFFFAOYSA-N phosphorus pentoxide Inorganic materials O1P(O2)(=O)OP3(=O)OP1(=O)OP2(=O)O3 DLYUQMMRRRQYAE-UHFFFAOYSA-N 0.000 description 1
210000002381 plasma Anatomy 0.000 description 1
231100000614 poison Toxicity 0.000 description 1
229920000768 polyamine Polymers 0.000 description 1
230000002265 prevention Effects 0.000 description 1
238000011321 prophylaxis Methods 0.000 description 1
230000001681 protective effect Effects 0.000 description 1
235000004252 protein component Nutrition 0.000 description 1
NPCOQXAVBJJZBQ-UHFFFAOYSA-N reduced coenzyme Q9 Natural products COC1=C(O)C(C)=C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)C(O)=C1OC NPCOQXAVBJJZBQ-UHFFFAOYSA-N 0.000 description 1
230000000241 respiratory effect Effects 0.000 description 1
239000012488 sample solution Substances 0.000 description 1
238000000926 separation method Methods 0.000 description 1
229940076279 serotonin Drugs 0.000 description 1
238000004904 shortening Methods 0.000 description 1
239000001632 sodium acetate Substances 0.000 description 1
235000017281 sodium acetate Nutrition 0.000 description 1
239000001488 sodium phosphate Substances 0.000 description 1
229910000162 sodium phosphate Inorganic materials 0.000 description 1
210000000278 spinal cord Anatomy 0.000 description 1
238000003860 storage Methods 0.000 description 1
208000023516 stroke disease Diseases 0.000 description 1
239000012609 strong anion exchange resin Substances 0.000 description 1
BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 1
239000011593 sulfur Substances 0.000 description 1
239000000829 suppository Substances 0.000 description 1
239000000725 suspension Substances 0.000 description 1
230000009897 systematic effect Effects 0.000 description 1
238000010998 test method Methods 0.000 description 1
238000004809 thin layer chromatography Methods 0.000 description 1
ZEMGGZBWXRYJHK-UHFFFAOYSA-N thiouracil Chemical compound O=C1C=CNC(=S)N1 ZEMGGZBWXRYJHK-UHFFFAOYSA-N 0.000 description 1
229950000329 thiouracil Drugs 0.000 description 1
229940113082 thymine Drugs 0.000 description 1
210000001685 thyroid gland Anatomy 0.000 description 1
239000003440 toxic substance Substances 0.000 description 1
231100000419 toxicity Toxicity 0.000 description 1
230000001988 toxicity Effects 0.000 description 1
150000003626 triacylglycerols Chemical class 0.000 description 1
UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 1
229940035936 ubiquinone Drugs 0.000 description 1
238000002211 ultraviolet spectrum Methods 0.000 description 1
210000003462 vein Anatomy 0.000 description 1
239000012610 weak anion exchange resin Substances 0.000 description 1
230000004580 weight loss Effects 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, ***e
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P19/00—Preparation of compounds containing saccharide radicals
- C12P19/26—Preparation of nitrogen-containing carbohydrates
- C12P19/28—N-glycosides
- C12P19/38—Nucleosides
- C12P19/40—Nucleosides having a condensed ring system containing a six-membered ring having two nitrogen atoms in the same ring, e.g. purine nucleosides

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
General Health & Medical Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Genetics & Genomics (AREA)
Zoology (AREA)
Wood Science & Technology (AREA)
Molecular Biology (AREA)
Biochemistry (AREA)
Biotechnology (AREA)
Diabetes (AREA)
Pain & Pain Management (AREA)
Neurosurgery (AREA)
Obesity (AREA)
General Engineering & Computer Science (AREA)
Psychiatry (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Hematology (AREA)
Microbiology (AREA)
Endocrinology (AREA)
Emergency Medicine (AREA)
Rheumatology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Saccharide Compounds (AREA)
Medicinal Preparation (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)

CS735374A 1972-08-02 1973-07-26 Method of producing tri-p-toluensulphonate s-adenosyl-l-methionine CS195254B2 (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
IT2779372		1972-08-02

Publications (1)

Publication Number	Publication Date
CS195254B2 true CS195254B2 (en)	1980-01-31

Family

ID=11222342

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CS735374A CS195254B2 (en)	1972-08-02	1973-07-26	Method of producing tri-p-toluensulphonate s-adenosyl-l-methionine

Country Status (29)

Country	Link
US (1)	US3893999A (de)
JP (1)	JPS5235726B2 (de)
AR (1)	AR195350A1 (de)
AT (1)	AT341684B (de)
AU (1)	AU474015B2 (de)
BE (1)	BE802981A (de)
CA (1)	CA1006872A (de)
CH (1)	CH592112A5 (de)
CS (1)	CS195254B2 (de)
DD (1)	DD107461A5 (de)
DE (1)	DE2336401C3 (de)
DK (1)	DK131868C (de)
ES (1)	ES417377A1 (de)
FI (1)	FI52466C (de)
FR (1)	FR2194425B1 (de)
GB (1)	GB1425384A (de)
HK (1)	HK31580A (de)
HU (1)	HU167266B (de)
IE (1)	IE37913B1 (de)
IL (1)	IL42764A (de)
MX (1)	MX4544E (de)
NL (1)	NL152864B (de)
NO (1)	NO137941C (de)
PL (1)	PL87381B1 (de)
RO (1)	RO63451A (de)
SE (1)	SE400085B (de)
SU (1)	SU646915A3 (de)
YU (1)	YU36037B (de)
ZA (1)	ZA734876B (de)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
IE39517B1 (en) *	1973-06-27	1978-10-25	Bioresearch Sas	Double salts of s-adenosyl-l-methhionine
AR221676A1 (es) *	1974-07-12	1981-03-13	Bioresearch Sas	Procedimiento para la preparacion de sales estables sulfonicas y/o sulfuricas de la s-adenosil-l-metionina,particularmente utiles como donadores especificos de metilo para las reacciones bioquimicas de transferencia del grupo ch3;asi como tambien las reacciones fundamentales en el metabolismo lipilico,protilico y glucidico
DE2646269A1 (de) *	1975-10-16	1977-04-28	Yamasa Shoyu Kk	Stabilisierte s-adenosyl-l-methionin- zubereitung und verfahren zur herstellung derselben
GB2064523B (en) *	1979-12-04	1983-06-29	Kanegafuchi Chemical Ind	Stable composition of s-adenosyl-l-methionine
IT1137640B (it) *	1981-08-24	1986-09-10	Bioresearch Srl	Sali stabili della s-adenosilmetionina,processo per la loro preparazione e composizioni terapeutiche che li comprendono come principio attivo
IT1137892B (it) *	1981-08-24	1986-09-10	Bioresearch Srl	Sali stabili della s-adenosilmetionina,processo per la loro preparazione e composizioni terapeutiche che li comprendono come principio attivo
IT1139974B (it) *	1981-09-11	1986-09-24	Bioresearch Srl	Derivati della s-adenosilmetionina,processo per la preparazione e composizioni terapeutiche che li contengono come principio attivo
IT1169773B (it) *	1983-08-24	1987-06-03	Bioresearch Spa	Processo per la produzione di sali stabili della solfo-adenosil-l-metionina
IT1169774B (it) *	1983-08-24	1987-06-03	Bioresearch Spa	Composizioni terapeutiche iniettabili contenenti sali stabili della s-adenosil-l-metionina
IT1173990B (it) *	1984-05-16	1987-06-24	Bioresearch Spa	Sali stabili della solfo-adenosil-l-metionina (same) particolarmente adatti per uso parenterale
IT1173992B (it) *	1984-05-16	1987-06-24	Bioresearch Spa	Sali stabili della solfo-adenosil-l-metionina (same) particolarmente idonei per uso farmaceutico orale
IT1200589B (it) *	1985-02-14	1989-01-27	Gibipharma Spa	Derivati naturali attivita farmagologica
AU2538588A (en) *	1987-10-09	1989-05-02	Mario De Rosa	Lipophilic salts of s-adenosyl-l-methionine (sam) with acylated taurine derivatives
DE19515275A1 (de) *	1995-04-26	1996-10-31	Knoll Ag	Neue Verwendung von (S)-Adenosyl-L-methionin(SAMe)
US6759395B2 (en)	2000-12-18	2004-07-06	Orchid Chemicals & Pharmaceuticals, Ltd.	Soft-gelatin capsule comprising S-adenosylmethionine and a method for producing the same
US8063024B2 (en) *	2005-01-26	2011-11-22	University Of Manitoba	Use of S-adenosylmethionine, vitamin E, and vitamin C for the treatment of oxidative liver injury and insulin resistance
US20090012036A1 (en) *	2005-05-24	2009-01-08	Hebert Rolland F	Stable S-adenosyl-L-methionine
ITMI20060629A1 (it) *	2006-03-31	2007-10-01	Daniele Giovannone	Composizioni solide orali a base di s-adenosilmetionina e processo per il loro ottenimento
EP2124552A4 (de) *	2007-01-31	2013-01-09	Methylation Sciences Internat Srl	Pharmazeutische formulierung aus s-adenosylmethionin mit verlängerter freisetzung
US20090197824A1 (en) *	2008-01-31	2009-08-06	Methylation Sciences International Srl	Extended Release Pharmaceutical Formulations of S-Adenosylmethionine
US20090088404A1 (en) *	2007-01-31	2009-04-02	Methylation Sciences International Srl	Extended Release Pharmaceutical Formulations of S-Adenosylmethionine
ITMI20071374A1 (it) *	2007-07-10	2009-01-11	Gnosis Spa	Sali stabili di s-adenosilmetionina e processo per il loro ottenimento.
US20100004191A1 (en) *	2008-07-01	2010-01-07	Rolland F Hebert	Compositions of S-adenosyl-L-methionine.
US20110027342A1 (en)	2009-07-28	2011-02-03	Msi Methylation Sciences, Inc.	S-adenosylmethionine formulations with enhanced bioavailability
US8329208B2 (en)	2009-07-28	2012-12-11	Methylation Sciences International Srl	Pharmacokinetics of S-adenosylmethionine formulations
US20140187509A1 (en) *	2011-04-15	2014-07-03	Scimar Ltd.	Use of s-adenosylmethionine, vitamin e, and vitamin c for the prevention and treatment of cardiovascular dysfunction
DK2753336T3 (en)	2012-10-17	2015-07-27	Methylation Sciences Internat Srl	COMPOSITIONS INCLUDING S-ADENOSYLMETHIONIN AND A BALLUS ACID ESTER
EP2945959B1 (de)	2013-01-16	2020-05-13	Hebert Sam-E LLC	Stabile indole-3-propionat salze von s-adenosyl-l-methionine

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US2946781A (en) *	1957-02-06	1960-07-26	Merck & Co Inc	Process for the preparation of adenosyl homocysteine
US3642772A (en) *	1968-09-04	1972-02-15	Boehringer Mannheim Gmbh	Process for preparing s-adenosyl homocysteine

1973
- 1973-07-16 IE IE1192/73A patent/IE37913B1/xx unknown
- 1973-07-17 DE DE2336401A patent/DE2336401C3/de not_active Expired
- 1973-07-17 US US380097A patent/US3893999A/en not_active Expired - Lifetime
- 1973-07-17 ZA ZA734876A patent/ZA734876B/xx unknown
- 1973-07-17 IL IL42764A patent/IL42764A/en unknown
- 1973-07-19 FR FR7326500A patent/FR2194425B1/fr not_active Expired
- 1973-07-19 GB GB3449973A patent/GB1425384A/en not_active Expired
- 1973-07-25 RO RO7300075582A patent/RO63451A/ro unknown
- 1973-07-26 CS CS735374A patent/CS195254B2/cs unknown
- 1973-07-26 YU YU2030/73A patent/YU36037B/xx unknown
- 1973-07-27 AT AT664173A patent/AT341684B/de not_active IP Right Cessation
- 1973-07-27 CA CA177,689A patent/CA1006872A/en not_active Expired
- 1973-07-27 AR AR249310A patent/AR195350A1/es active
- 1973-07-30 AU AU58680/73A patent/AU474015B2/en not_active Expired
- 1973-07-30 ES ES417377A patent/ES417377A1/es not_active Expired
- 1973-07-30 BE BE134028A patent/BE802981A/xx not_active IP Right Cessation
- 1973-08-01 DK DK422773A patent/DK131868C/da not_active IP Right Cessation
- 1973-08-01 HU HUEE2163A patent/HU167266B/hu unknown
- 1973-08-01 NO NO3084/73A patent/NO137941C/no unknown
- 1973-08-01 SU SU731945967A patent/SU646915A3/ru active
- 1973-08-01 PL PL1973164439A patent/PL87381B1/pl unknown
- 1973-08-01 SE SE7310587A patent/SE400085B/xx unknown
- 1973-08-01 DD DD172669A patent/DD107461A5/xx unknown
- 1973-08-01 MX MX737933U patent/MX4544E/es unknown
- 1973-08-02 JP JP48086440A patent/JPS5235726B2/ja not_active Expired
- 1973-08-02 CH CH1125173A patent/CH592112A5/xx not_active IP Right Cessation
- 1973-08-02 FI FI732438A patent/FI52466C/fi active
- 1973-08-02 NL NL737310706A patent/NL152864B/xx not_active IP Right Cessation
1980
- 1980-06-12 HK HK315/80A patent/HK31580A/xx unknown

Also Published As

Publication number	Publication date
ES417377A1 (es)	1976-02-16
YU36037B (en)	1981-11-13
NO137941B (no)	1978-02-13
YU203073A (en)	1981-04-30
FR2194425A1 (de)	1974-03-01
NL7310706A (de)	1974-02-05
AU474015B2 (en)	1976-07-08
DK131868C (da)	1976-03-08
DE2336401B2 (de)	1979-07-12
CA1006872A (en)	1977-03-15
NO137941C (no)	1978-05-31
FI52466B (de)	1977-05-31
IL42764A0 (en)	1974-01-14
JPS5235726B2 (de)	1977-09-10
SE400085B (sv)	1978-03-13
DD107461A5 (de)	1974-08-05
US3893999A (en)	1975-07-08
MX4544E (es)	1982-06-08
BE802981A (fr)	1973-11-16
PL87381B1 (de)	1976-06-30
GB1425384A (en)	1976-02-18
RO63451A (fr)	1978-07-15
CH592112A5 (de)	1977-10-14
AT341684B (de)	1978-02-27
IE37913B1 (en)	1977-11-09
IL42764A (en)	1976-04-30
AU5868073A (en)	1975-01-30
ZA734876B (en)	1974-06-26
ATA664173A (de)	1977-06-15
FR2194425B1 (de)	1976-04-09
DE2336401A1 (de)	1974-02-14
DE2336401C3 (de)	1980-03-13
NL152864B (nl)	1977-04-15
AR195350A1 (es)	1973-09-28
JPS4992215A (de)	1974-09-03
SU646915A3 (ru)	1979-02-05
HK31580A (en)	1980-06-20
IE37913L (en)	1974-02-02
DK131868B (da)	1975-09-15
FI52466C (fi)	1977-09-12
HU167266B (de)	1975-09-27

Publication	Publication Date	Title
CS195254B2 (en)	1980-01-31	Method of producing tri-p-toluensulphonate s-adenosyl-l-methionine
FI60218B (fi)	1981-08-31	Foerfarande foer framstaellning av terapeutiskt anvaendbara dubbelsalter av s-adenosyl-l-metionin
FI63037B (fi)	1982-12-31	Foerfarande foer framstaellning av terapeutiskt anvaendbara stbila sulfonater av s-adenosyl-l-metionin
Finkelstein et al.	1974	Ethanol-induced changes in methionine metabolism in rat liver
Hyland et al.	1988	Demyelination and decreased S‐adenosylmethionine in 5.10‐methylenetetrahydrofolate reductase deficiency
Wendel et al.	1984	Betaine in the treatment of homocystinuria due to 5, 10-methylenetetrahydrofolate reductase deficiency
EP0057942B1 (de)	1985-09-11	System zur Produktion von Cystein
EP0072980A1 (de)	1983-03-02	Stabile Salze von S-Adenosinylmethionin, Verfahren zu ihrer Herstellung und pharmazeutische Zusammensetzungen welche als aktive Substanz diese Derivate enthalten
JPH0630607B2 (ja)	1994-04-27	非経口用に特に適した安定なスルホ‐アデノシル‐ｌ‐メチオニン塩
US5227518A (en)	1993-07-13	L-carnitine derivatives as therapeutical agents for treating myopathies and neuronal degeneration and for inhibiting proteolysis
CZ279834B6 (cs)	1995-07-12	Stálé soli S-adenosylmethioninu a způsob jejich výroby
NO153397B (no)	1985-12-02	Analogifremgangsmaate ved fremstilling av stabile s-adenosylmethioninestere.
US4028183A (en)	1977-06-07	Process of preparing double salts of S-adenosyl-L-methionine
Elvehjem et al.	1943	The Structure and Estimation of Natural Products Functionally Related to Nicotinic Acid.
US20050272687A1 (en)	2005-12-08	Stable S-adenosyl-l-methionine
RU2709500C1 (ru)	2019-12-18	Фармацевтическая композиция для парентерального капельного введения
Wilhelmj et al.	1928	STUDIES ON THE PHYSIOLOGY OF THE LIVER: XVII. The Effect of Removal of the Liver on the Specific Dynamic Action of Amino Acids Administered Intravenously
Thurston et al.	1986	β-Hydroxybutyrate reverses insulin-induced hypoglycemic coma in suckling-weanling mice despite low blood and brain glucose levels
Macrae et al.	1939	Observations on the liver filtrate factor of the vitamin B2 complex
US20120040923A1 (en)	2012-02-16	Stable s-adenosyl-l-methionine
US6635615B1 (en)	2003-10-21	Stable salts of S-adenosyl-l-methionine
SU1433416A3 (ru)	1988-10-23	Способ получени S-аденозилметиониновых (САМ) солей
Bessman et al.	1991	Ammonia inhibits insulin stimulation of the Krebs cycle: further insight into mechanism of hepatic coma
Stewart	1949	Adenine compounds, their chemical, physiological, and therapeutic properties
CN117599091A (zh)	2024-02-27	牛黄在制备预防或治疗高尿酸血症药物中的应用